• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Membrane-based approach for the downstream processing of influenza virus-like particles

tetano

Editor, Senior Moderator
Biotechnol J. 2019 May 20:e201800570. doi: 10.1002/biot.201800570. [Epub ahead of print]
[h=1]Membrane-based approach for the downstream processing of influenza virus-like particles.[/h] Carvalho SB[SUP]1,[/SUP][SUP]2[/SUP], Silva R[SUP]1[/SUP], Moleirinho MG[SUP]1[/SUP], Cunha B[SUP]1,[/SUP][SUP]2[/SUP], Moreira AS[SUP]1[/SUP], Xenopoulos A[SUP]3[/SUP], Alves PM[SUP]1,[/SUP][SUP]2[/SUP], Carrondo MJT[SUP]1[/SUP], Peixoto C[SUP]1,[/SUP][SUP]2[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] Currently marketed influenza vaccines are only efficient against homologous viruses, thus requiring a seasonal update based on circulating subtypes. This constant reformulation adds several challenges to manufacturing, particularly in purification due to the variation of the physicochemical properties of the vaccine product. A universal platform approach capable of handling such variation is therefore of utmost importance. In this work, a filtration-based approach is explored to purify influenza virus-like particles. Switching from adsorptive separation to size-based purification allows overcoming the differences in retention observed for different influenza strains. The proposed process employs a cascade of ultrafiltration and diafiltration steps, followed by a sterile filtration step. Different process parameters were assessed in terms of product recovery and impurities' removal. Membrane chemistry, pore size, operation modes, critical flux, transmembrane pressure, and permeate control strategies were evaluated. After membrane selection and parameter optimization, concentration factors and diafiltration volumes were also defined. By optimizing the filtration mode of operation, we were able to achieve product recoveries of approximately 80%. Overall, we decreased process time by 30%, improved its scalability and reduced the costs due to the removal of chromatography and associated buffer consumptions, cleaning and its validation steps. This article is protected by copyright. All rights reserved.
This article is protected by copyright. All rights reserved.


[h=4]KEYWORDS:[/h] Filtration; Influenza; Tangential Flow Filtration; Vaccines; Virus-like particles

PMID: 31106962 DOI: 10.1002/biot.201800570
 
Back
Top Bottom